Compare VBNK & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VBNK | SLBT |
|---|---|---|
| Founded | 1980 | N/A |
| Country | Canada | Taiwan |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.7M | 644.9M |
| IPO Year | 2016 | 2025 |
| Metric | VBNK | SLBT |
|---|---|---|
| Price | $22.53 | $1.23 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.50 | N/A |
| AVG Volume (30 Days) | ★ 81.7K | 45.1K |
| Earning Date | 12-09-2026 | 10-26-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.02 | N/A |
| Revenue Next Year | $37.94 | N/A |
| P/E Ratio | $25.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $1.02 |
| 52 Week High | $24.42 | $6.25 |
| Indicator | VBNK | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 30.34 |
| Support Level | $21.51 | N/A |
| Resistance Level | $23.24 | $1.75 |
| Average True Range (ATR) | 0.60 | 0.14 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 26.73 | 26.03 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.